NeuroMetrix (NSDQ:NURO) said today it won regulatory approval in China for its DPNCheck diagnostic test for peripheral neuropathy. DPNCheck is a point-of-care-test designed to detect diabetic peripheral neuropathy at an early stage to allow for appropriate treatment. NeuroMetrix said that DPN is the most common complication of diabetes, and affects more than 50% of people with […]
NeuroMetrix (NSDQ:NURO) saw shares jump as high as 37% yesterday after announcing it won FDA 510(k) clearance for an upgraded version of its Quell wearable over-the-counter chronic pain relief device, though shares haven’t held onto the inertia in trading today. The new model is designed to be controlled through a company-developed smartphone app, and has an […]
NeuroMetrix (NSDQ:NURO) said yesterday it inked a securities purchase agreement with a private institutional healthcare investor for 13,800 shares of Series C convertible preferred stock at $1,000 per share, raking in $13.8 million total. The round also included 2 series of warrants to purchase approximately 10.8 million shares of common stock at $2.30 per share, according […]
NeuroMetrix (NSDQ:NURO) said today it consummated its 1 for 4 reverse split of its common stock, trading at a split-adjusted basis yesterday. Stocks rose on Tuesday to open at $3.01, but dropped to close at $2.65. Today, shares of NURO opened at $2.70 and fell over 6% to close at $2.43, down roughly 19% from its opening price on […]
NeuroMetrix (NSDQ:NURO) said it underwent a 1-for-4 reverse split of its common stock, effective today. The move is being made to increase per share trading price to satisfy the NASDAQ Capital Market’s $1.00 minimum bid price requirement, NeuroMetrix said.. As a result, every 4 shares of the Waltham, Mass.-based company’s stock will be consolidated into 1 issued […]
NeuroMetrix (NSDQ:NURO) released preliminary data on Tuesday from a clinical study of its Quell wearable pain relief device for patients with chronic pain. The study found that 81% of the patients reported improvements in chronic pain levels and overall health after 60-days of using the device, Waltham, Mass.-based NeuroMetrix said. “We are pleased with these results. […]
NeuroMetrix (NSDQ:NURO) said yesterday it signed a deal with supply chain company Advantage Consumer Healthcare to expand the distribution of its Quell wearable pain relief device. The new deal will position ACH to distribute the pain relief device to the retail sector, including mass merchandisers and chain drug stores, Waltham, Mass.-based NeuroMetrix said. “We are excited […]
NeuroMetrix (NSDQ:NURO) said last week that it raised $14.7 million in its most recent funding round. Waltham, Mass.-based NeuroMetrix said it sold 147,000 shares at $100 per share and repurchased all of the outstanding shares of its Series A-4 convertible preferred stock for approximately $3.2 million. The proceeds are slated to be used to fund the commercial […]
As 2014 draws to a close, MassDevice.com asked several medical device company CEOs for their takes on 2014 and what they’re looking for in 2015.
We wanted to get their views on the major trends seen in medtech this year, including the red-hot M&A and IPO scenes, the medical device tax, the regulatory environment in the U.S., and more.